team-Tia-Bush

Tia Bush

Chief Technology and Quality Officer

Tia Bush serves as Chief Technology and Quality Officer for Centessa Pharmaceuticals. Tia is a global leader who brings nearly thirty years of biotechnology quality experience to the company.

Tia’s extensive career has been spent in quality-related roles of increasing responsibility at Amgen, Inc., where she joined in 1993. Most recently, Tia was Chief Quality Officer and Senior Vice President, Global Quality/Environment, Health, Safety and Sustainability where she was responsible for developing, maintaining, and continuously improving the quality management and EHSS management systems. She led an organization of more than 1,400 quality and safety professionals.

Tia currently sits on the Board of Directors for PDA and USC Health Services. She holds a BA in Biological Sciences with a minor in Chemistry from the University of Southern California, Los Angeles, USA.

Scroll to Top
;
pipeline chart header registrational white
SerpinPC

Overview
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for hemophilia, regardless of severity or inhibitor status, and may also prevent bleeding associated with other bleeding disorders. Centessa is advancing the registrational program for SerpinPC in hemophilia B, which includes a set of clinical studies with multiple components. PRESent-5, initiated in late 2022, is an observational feeder study to collect prospective observational data for minimum defined periods before switching to dosing subjects in the interventional studies. The interventional studies include PRESent-2 (moderately severe to severe hemophilia B without inhibitors, and severe hemophilia A with and without inhibitors) and PRESent-3 (hemophilia B with inhibitors). Additional information on the trials can be accessed at www.clinicaltrials.gov  (NCT05605678NCT05789524NCT05789537). SerpinPC is an investigational agent that has not been approved by the FDA or any other regulatory authority.

Reason to Believe in Target
Human Genetics Support

Epidemiology
~20,000 persons with hemophilia in the United States
450,000 estimated global prevalence
Disease

Hemophilia B